波纳替尼:关于其药物标,治疗潜力和安全性的最新情况
Yue Gao1, Yue Ding1, Xin-Ran Tai1
1State Key Laboratory of Southwestern Chinese Medicine Resources, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China.
Biochimica et biophysica acta. Reviews on cancer
|July 3, 2023
概括
波纳替尼 (Ponatinib) 是第三代氨酸激酶抑制剂 (TKI),有效对抗白血病和其他癌症. 需要制定策略来减轻其显著的心血管毒性,以便在临床上更安全地使用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 白血病是一种具有不断发展的治疗策略的造血性恶性瘤.
- 氨酸激酶抑制剂 (TKIs) 是白血病治疗的重大进展.
- 波纳替尼是第三代BCR-ABL TKI,已证明有效性,但存在心血管毒性挑战.
研究的目的:
- 审查ponatinib的药理动力学,标,治疗潜力和生产机制.
- 讨论与ponatinib相关的显著心血管毒性.
- 探索减轻ponatinib毒性和提高其临床安全的策略.
主要方法:
- 对ponatinib的特性和临床数据的文献综述.
- 对ponatinib多位激酶抑制特征的分析.
- 检查报告的心血管毒性和潜在的管理策略.
主要成果:
- 波纳替尼 (Ponatinib) 是一种强大的多标TKI,其应用范围超出白血病,包括TNBC和肺癌.
- 显著的心血管毒性是波纳替尼的临床使用的主要限制.
- 了解ponatinib的机制和毒性对于开发更安全的治疗方法至关重要.
结论:
- 波纳替尼由于其广泛的激酶抑制,在各种恶性瘤中提供了有前途的治疗方法.
- 解决ponatinib的心血管毒性对于扩大其临床效用至关重要.
- 对降低毒性策略的进一步研究对于提高ponatinib的安全性概况至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


